Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA 15.3

British Journal of Cancer

Volumn 74, Issue 7, 1996, Pages 1126-1131

  Molina, R ^a,d   Jo, J ^a   Zanon G ^a   Filella, X ^a   Farrus, B ^a   Munoz M ^b   Latre, M L ^c   Pahisa, J ^a   Velasco, M ^c   Fernandez, P ^d   Estape J ^b   Ballesta, A M ^a  

^a Institute of Neurosciences   (Spain)

^b School of Medicine   (Spain)

^c School of Medicine   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer; c erbB 2; CA 15.3; Carcinoembryonic antigen; Tumour marker; Tumour associated antigen

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; BONE METASTASIS; BREAST CANCER; CANCER RECURRENCE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE C ERB; PRIORITY JOURNAL; TISSUE LEVEL;

EID: 10144247242     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.501     Document Type: Article

References (27)

1. AHLEMANN LM, STAAB HJ AND ANDERER FA. (1980). Serial CEA determinations as an aid in postoperative therapy management of patients with early breast cancer. Biomedicine, 32, 194 - 199.
2. ALBURQUERQUE KV, PRICE MR, BADLEY RA, JONRUP I, PEARSON D, BLAMEY RW AND ROBERTSON JFR. (1995). Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur. J. Surg. Oncol., 21, 504 509.
3. ALLRED DC, CLARK GM, MOLINA R, TANDON AK, SCHNITT SJ, GILHRIST KW, OSBORNE CK, TORMEY DC, ABELOFF MD AND MCGUIRE WL. (1992a). Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in-situ to invasive breast cancer. Hum. Pathol., 23, 974 - 979.
4. ALLRED DC, CLARCK GM, TANDON AK, MOLINA R, TORMEY DC, OSBORNE CK, GILHRIST KW, MANSOUR EG, ABELOFF MD AND MCGUIRE WL. (1992b). HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 4, 599 - 605.
5. ALTMAN DG. (1991). Practical Statistics for Medical Research. Chapman-Hall: London.
6. CASES A, FILELLA X, MOLINA R, BALLESTA AM, LOPEZ-REVERT J AND REVERT L. (1991). Tumor markers in chronic renal failure and hemodialysis patients. Nephron, 57, 183 - 186.
7. CHATAL JF, CHUPIN G, RICOLLEAU G, TELLIER JL, LE MOVEL A AND FUMOLEAU P. (1981). Use of serial carcinoembryonic antigen assays in detecting relapses in breast cancer involving high risk of metastasis. Eur. J. Cancer, 17, 233 - 238.
8. COLOMER R, RUIBAL A, GENOLLA J AND SALVADOR L. (1989). Circulating CA 15.3 antigen levels in non-mammary malignancies. Br. J. Cancer, 59, 283 - 286.
9. COOMBES R, POWLES T, GAZET J, FORD HT, MCKINNA A, ABBOT M, GEHRKE CN, KEYSES JW, MITCHELL PEG, PATEL S, STIMSON WH, WORWOOD M, JONES M AND NEVILLE AM. (1981). Screening for metastases in breast cancer: an assessment of biochemical and physical methods. Cancer, 48, 310 - 315.
10. DAVIDSON NE AND LIPPMAN ME. (1988). Adjuvant therapy for breast cancer. In Diagnosis and Management of Breast Cancer, Lippman ME, Lichter AS and Danforth DN. (eds) pp. 348 - 387. WB Saunders: Philadelphia.
11. DE VITA VT Jr. (1983). The relationship between tumour mass and resistance to chemotherapy. Cancer, 51, 1209 - 1220.
12. GOLDIE JH. (1989). Mathematical models of drug resistance and chemotherapy effects. In Drug Resistance in Cancer Therapy, Ozols RF. (ed.) pp. 13 - 26. Kluwer Academic: Boston.
13. KUFE D, INGHIRAMI G, ABE M, MAYES D, JUSTI-WHEELER H AND SCHLOM J. (1984). Differential reactivity of a novel monoclonal antibody (DF-3) with human malignant versus benign breast tumor. Hybridoma, 3, 223 - 232.
14. MCKENZIE SJ, DE SOMBRE KA, BAST BS, HOLLIS DR, WHITAKER RS, BERCHUCK A, BOYER CM AND BAST RC. (1993). Serum levels of HER-2/neu (C-erbB-2) correlate with overexpression of p184 neu in human ovarian cancer. Cancer, 71, 3942 - 3946.
15. MINTON JP, HOENH JL, GERBER DM, SHELTON J, CONNALLY DP AND SALWAN F. (1985). Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer, 55, 1284 - 1290.
16. MOLINA R AND BALLESTA AM. (1991). Evaluation of several tumor markers (MCA, CA 15.3, BCM and CA 549) in tissue and serum of patients with breast cancer. In Breast Epithelial Antigens. Molecular Biology to Clinical Applications, Ceriani RL. (ed.), pp. 161 - 168. Plenum Press: New York.
17. MOLINA R, FILELLA X, MENGUAL PJ, PRATS M, ZANON G, DANIELS MD AND BALLESTA AM. (1990). MCA in patients with breast cancer: correlation with CEA and CA 15.3. Int. J. Biol. Markers, 5, 14 - 21.
18. MOLINA R, CIOCCA R, TANDON AK, ALLRED DC, CLARCK GC, CHAMNESS GC, GULLICK WJ AND MCGUIRE WL. (1992). Expression of HER-2/neu oncoprotein in human breast cancer. A comparison of immunohistochemical and western blot techniques. Anticancer Res., 12, 1965 - 1972.
19. MOLINA R, ZANON G, FILELLA X, MORENO F, JO J, DANIELS M, LATRE ML, GIMENEZ N, PAHISA J, VELASCO M AND BALLESTA AM. (1995). Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Br. Cancer Res. Treat., 36, 41 - 48.
20. MOLINA R, JO J, FILELLA X, BRUIX J, GIMENEZ N, CASTELLS A, HAGUE M AND BALLESTA AM. (1996). Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumor Biol., (in press).
21. NARITA T, FUNAHASHI H, SATOH Y AND TAKAGI H. (1992). C-erbB-2 in the sera of breast cancer patients. Br. Cancer Res. Treat., 24, 97 - 102.
22. PUPA SM, MENARD S, MORELLI D, POZZI B, DE PALO G AND COLNAGHI MI. (1993). The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8, 2917 - 2923.
23. SILVESTRINI R, SANFILIPPO O AND TEDESCO G. (1974). Kinetics of human mammary carcinoma and their correlation with the cancer and the host characteristics. Cancer, 34, 1252 - 1258.
24. SLAMON DJ, GODOLPHIN W, JONES LA, HOLT JA, WONG SG, KETH DE, LEVIN WJ, STUART SG, UDOBE J, ULLRICH A AND RESS MF. (1989). Studies of the HER-2 neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707 - 712.
25. STAAB HJ, AHLEMANN ML, KOCH HL AND ANDERER FA. (1980). Serial carcinoembryonic antigen determinations in the management of patients with breast cancer. Oncodev. Biol. Med., 1, 151 - 160.
26. VAN DALEN A. (1989). Tumor markers in breast cancer. Ann. Ch. Gynaec., 78, 54 - 64.
27. ZABRECKY JR, LAM T, MCKENZIE SJ AND CARNEY W. (1991). The extracellular domain of p 185 neu is released from the surface of human breast carcinoma cell, SK-BR-3. J. Biol. Chem., 266, 1716 - 1720.